115 results about "Structured lipid" patented technology

The invention discloses an application of nanometer structure lipid carrier administration system in the antineoplastic drug to reverse the multiple-drug tolerance of tumour cell, which comprises the following parts: solid lipid material, liquid lipid material and antineoplastic drug, wherein the rate of the liquid lipid (such as oleic acid) is 0-30wt%; the solid lipid is selected from monoglyceride; the liquid lipid is oleic acid; the antineoplastic drug is Paclitaxel or adriablastina. The invention has highly effective cell uptaking and cytolymph condensing function with packing molecular target in the antineoplastic drug of cell, which avoids P-glucoprotein in the drug tolerant cytolymph from identifying the antineoplastic drug to reduce exclusion.

Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided.

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

A novel oil composition comprises an interesterified structured lipid component, the component being an interesterifcation reaction product of an amount of a medium chain triglyceride, an amount of a long chain domestic oil, and an amount of a conjugated linoleic acid material. The structured lipid component can be used in edible oil compositions. The oil compositions advantageously can contain an amount of a phytosterol ester component, up to about 12 weight percent of the total composition. The oil compositions disclosed herein have good stability and also have other properties useful for an edible oil composition.

The invention relates to candida Antarctica lipase B gene and applications thereof in yeast display. Coded protein of improved candida Antarctica B and wild type candida Antarctica lipase protein have the same function on the amino acid level; the heat resistance capacity of the enzyme is 50-80 DEG C, and the half-lift is 3-24 hours; a nucleotide sequence is hybridized with SEQ.ID.NO2 from 1st to 978th of nucleotide under the moderate precise condition; and a preservation number of colon bacillus DH5Alpha/Puc57-CALB (Escherichia coliDH5Alpha/pUC57-CALB) which carries the plasmids is CCTCC M 209081. The candida Antarctica lipase B gene is transferred into pichia pastoris host bacteria so as to realize the high-efficient display expression of the candida Antarctica lipase B in pichia pastoris; and the provided pichia pastoris bacteria can effectively display candida Antarctica lipase B, can be widely applied to the synthesis of ethyl caproate, has different melting points and does not contain triglyceride of various fatty acids, a plurality of structured lipids, and the like.

Methods and composition are described for low immunogenic protein, polypeptide or peptide formulations. The method comprises forming complexes of the protein, polypeptide or peptide with a binding agent which can be a serine containing compound or other phosphatidyl compounds or phospholipids. The complexes formed include simple complexes, micelles, cochleate structures, liposomes, non-bilayer and novel lipidic structures. The antigenicity and imminogenicity of the protein, polypeptides or peptides is reduced upon formation of such complexes.

A method is disclosed for making reduced calorie cultured cheeses whereby the natural lipid content of milk is replaced with colloidal forms of synthetic or chemically structured lipids displaying low to no human digestibility. The colloidal dispersion of modified lipids contained within the milk base is initially stabilized by preferred combinations of polymeric and particulate hydrocolloidal materials such as structurally expanded cellulose. Such stabilization is important during formation of the curd to ensure homogeneous distribution and maintenance of the lipid dispersion throughout the coagulum yet allow effective concentration of the coagulum solids by means of ordinary water removal methods commonly used in the manufacture of conventional cultured cheeses. The coagulum is then processed by means similar to that employed for naturally fermented cheeses. The resulting cultured cheese is a reduced calorie product with low to no metabolizable fat content yet possesses organoleptic properties similar to a full fat product.

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

Lipid compositions comprising specific mixtures of edible synthetic triglycerides are provided that are useful in formulating food products having highly desirable dietary benefits. The novel lipid compositions allow simultaneous access to highly desirable dietary benefits such as delivery of calorie reduction, weight management, health benefits, or any combination thereof, and they also may be formulated trans-fatty acid free.

The invention discloses a method for determining compositions of fatty acids and acylglycerols at alpha and beta positions of structured lipid by combining solid-phase extraction and gas chromatography. The method comprises utilizing pure arachidonic acid-triacylglycerol (ARA-TAG), docosahexaenoic acid-diacylglycerol (DAH-DAG), linolenic acid- monoacylglycerol (Ln-MAG) and an oleic acid-free fatty acid (O-FFA) standard sample, and optimizing eluent elution conditions with different polarity ratios, so as to effectively separate TAG, DAG, MAG and FFA in mixtures in a same SPE (Solid Phase Extraction) microcolumn; and the method is characterized by also comprising the following steps: 1) separation of a mixed standard sample and analysis on compositions of fatty acids; and 2) analysis on compositions of fatty acids and acylglycerols at alpha and beta positions of the structured lipid. The method has the advantages of simple operation, low sample demanded amount, less consumption amount of a needed solvent, accurate qualitative quantitative analysis results, low detection limit and short analysis time, and is capable of realizing high-flux detection on TAG, DAG, MAG and FFA compositions and content in structured lipid and compositions of fatty acids at alpha and beta positions of structured lipid.

The invention discloses an enzymatic acidolysis-based method for synthesizing structured lipids from palmitic acid triglycerides. The method comprises the following steps: saponifying and refluxing an oil raw material and a solvent in nitrogen; after complete hydrolysis, recovering the solvent in a spin steaming manner, and regulating the pH value of a hydrolysis mixture; extracting free fatty acids after washing, removing water from anhydrous magnesium sulfate and filtering so as to obtain filtrate; carrying out spin steaming on the filtrate, so as to obtain the free fatty acids; and mixing at least one of the free fatty acids with the palmitic acid triglycerides, and preparing the structured lipids under the action of the sn-1,3-bit specific lipase. According to the method, the palmitic acid triglycerides and the fatty acids are catalyzed by the sn-1,3-bit specific lipase to directionally synthesize the structured lipids; MLM-type structured lipids are prepared from short-carbon chain saturated fatty acids and the palmitic acid triglycerides, which are easy to digest and absorb, in a manner of enzymatic acidolysis; meanwhile, LPL-type structured lipids are prepared from long-chain unsaturated fatty acids and the palmitic acid triglycerides, which are essential to the body, in the manner of enzymatic acidolysis; and different types of structured lipids can be configured according to the different nutritional requirements of different people.

The invention discloses 5'-amino-2',5'-dideoxynucleotide phospholipid molecules, and a preparation method and an application thereof. The 5'-amino-2',5'-dideoxynucleotide phospholipid molecules provided by the invention have an amphiphilic structure represented by the formula (I). 5'-amino-2',5'-dideoxynucleoside is adopted as a hydrophilic head, and glycerol fatty ether connected by using a phosphate bond is adopted as a hydrophobic tail, such that an amphiphilic molecule is formed. The Base group is common purine and pyrimidine bases, and R group is saturated or unsaturated aliphatic carbon chain. In a water-phase solvent, the dideoxynucleotide phospholipid molecule can form a plurality of supramolecular structures including multi-layer film structure, lipid structure, fibrous structure, and hydrogel. Therefore, 5'-amino-2',5'-dideoxynucleotide phospholipid molecules have certain potential to be used as aggregation, trapping, loading, or carrying type nucleic acid medicines, and can be used as a high-efficiency biological material for mediating transmembrane of nucleic acid medicines.

PURPOSE: A method for preparing a nanostrucutured lipid carrier or nanoemulsion is provided to reduce inflammation and to ensure chemical stability. CONSTITUTION: A method for preparing a nanostrucutured lipid carrier or nanoemulsion comprises: a step of dissolving an oil phase at higher temperature than the temperature of an oil phase containing solid lipid, liquid lipid, or mixture thereof and lipophilic and hydrophilic surfactant; a step of adding active ingredients to the dissolved oil phase; a step of homogenizing the oil phase; a step of mixing the oil phase with a first aqueous solution and preheating; a step of forming pre-emulsion; and a step of homogenizing the pre-emulsion.

The invention relates to a clevidipine butyrate structured lipid emulsion which comprises clevidipine butyrate, structured triglyceride, an emulsifier, an isotonic agent, a pH regulator, and injection water, wherein the weight volume percentage of clevidipine butyrate is 0.05-0.1% (w/v); the weight volume percentage of structured triglyceride is 5-30% (w/v); the weight volume percentage of the emulsifier is 1.0-2.0% (w/v); and the weight volume percentage of the isotonic agent is 1.0-5.0% (w/v).

The invention discloses a lipase mutant with improved enzyme activity and regioselectivity and application of the mutant and belongs to the technical field of gene engineering. According to the lipasemutant, wild-type lipase is mutated, the enzyme activity of mutants M8A, L10A, D11A, L12A and P17G is increased by 1.1-2.4 times compared with the enzyme activity of wild-type lipase, and the 1,3-regioselectivity of the mutants M8A, L10A and T9A is increased by 4.75-5 times compared with the regioselectivity of wild-type lipase. The enzyme activity and regioselectivity are important parameters ofthe lipase mutant in structural lipid catalytic application. The lipase mutant is applied to a catalytic reaction of human milk fat substitutes and has an obvious effect.

Unique structured lipids obtained from interesterifying coconut oil with free fatty acids obtained from hydrolysis of triglycerides of vegetable source, said structured lipids rich in omega 6 polyunsaturated fatty acids and medium chain fatty acids and a process for the production of said structural lipids.

The invention provides a humanized infant formula milk powder which contains nucleotides and OPO structured lipid, and is used for infants of 0 to 12 months older, and a preparation method thereof. In the humanized infant formula milk powder, the content of total protein ranges from 10.5 to 18g/100g, the amount of whey protein accounts for 48 to 61% of that of total protein, the content of alpha-whey protein ranges from 1.25 to 1.8g/100g, the content of beta-casein ranges from 2.2 to 3.7g/100g, the content of fat ranges from 20 to 29g/100g, the content of linoleic acid ranges from 2600 to 4500mg/100g, the content of alpha-linolenic acid ranges from 330 to 450mg/100g, the content of 1,3-dioleoyl-2-palmitoylglycerol ranges from 3 to 5g/100g, the content of carbohydrate ranges from 52 to 56g/100g, and the content of total nucleotides ranges from 26 to 58mg/100g in total nucleotide molecular weight. The humanized infant formula milk powder is more similar to breast milk, and is capable of improving infant immunity.

A composition in the form of a dry powder and which comprises: a) at least one membrane lipid, and b) at least one biologically active compound comprising a xanthine and/or a carboxylic acid, and which forms structured lipid assemblies when dispersed/dissolved in an aqueous medium. A method of preparing such a composition is also provided, together with a dispersion of structured lipid assemblies suspended in a solution of at least one biologically active compound and a method of preparing the same. The compositions and dispersions are suitable for use in creams and lotions for skin care.

Lipid compositions are provided exhibiting the functionality of a typical shortening or filler fat, but are achieved with reduced and essentially zero trans-unsaturated fatty acids and that deliver reduced caloric content. By one approach, the functional lipid compositions include a blend of a matrix building ingredient, which is preferably a structured glycerol ester, and an edible liquid oil diluent in ratios such that the lipid composition exhibits the functionality of the traditional shortening or filler fat.

Disclosed is a method for preparing a CLA-enriched structured lipid by a transesterification of medium chain triglyceride (MCT) with ester or free fatty acid form of CLA using lipases, and use of the same. It has been known that CLA mainly exists in an acid form, and has various beneficial biological activities, but rapid oxidation property during storage. And also, animal fat or plant oil, widely ingested by animals or humans, is naturally produced as an acylglycerol form containing various fatty acids. The CLA-containing structured lipid is manufactured by mixing free or ester form of CLA with acylglyceride at a molar ratio of 1:1~1:5, adding immobilized lipase of 2.2~20% by weight of CLA and acylglyceride to the mixture with a solvent, and incubating at 35~75° C. for 1-36 hours. The CLA-containing structured lipid is a natural TG form and contains a high content of CLA, characterized by at least 15% content of CLA in total fatty acid composition, and at least 5% of CLA at sn-2 position. Accordingly, with the CLA-enriched MCT being administrated, it can efficiently provide biological activities of CLA, such as inhibition of carcinogenesis and reduction of fat accumulation in a body, as well as rapidly supply calories, an innate nutritional property of MCT.